肝硬変治療の市場規模、シェア、成長分析：疾患タイプ別、治療タイプ別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

肝硬変治療の世界市場規模は、2023年に177億6,000万米ドルと評価され、2024年の189億米ドルから2032年には310億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.4％で成長する見通しです。

著しい肝障害と瘢痕化を特徴とする肝硬変は、特にライフスタイルの変化に関連した肝疾患の有病率の上昇を考えると、世界の健康上の大きな脅威となっています。肝硬変治療市場成長の主な促進要因には、アルコール消費量の増加や食生活の乱れとともに、現在世界で約15億人が罹患している慢性肝疾患の罹患率の上昇が含まれます。特に、非アルコール性脂肪性肝疾患（NAFLD）が主な原因として浮上しており、その有病率は2040年までに55.7％に達するとの予測もあります。さらに、B型肝炎とC型肝炎は、肝硬変と肝細胞がんのリスクを悪化させ、かなりの死亡率をもたらすという重大な懸念を残しています。そのため、大手製薬会社は効果的な肝疾患治療薬の開発に力を注いでいます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

肝硬変治療市場規模：疾患タイプ別& CAGR（2025-2032）

• 市場概要
• アルコール性肝硬変
• 萎縮性肝硬変
• 胆汁性肝硬変
• 原因不明の肝硬変

肝硬変治療市場規模：治療タイプ別& CAGR（2025-2032）

• 市場概要
• 免疫抑制剤
• 抗生物質
• ワクチン
• 抗ウイルス薬
• コルチコステロイド

肝硬変治療市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• その他

肝硬変治療市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Gilead Sciences（United States）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• AstraZeneca（United Kingdom）
• Bayer AG（Germany）
• Sanofi（France）
• AbbVie Inc.（United States）
• GlaxoSmithKline PLC（United Kingdom）
• Bristol-Myers Squibb Company（United States）
• Alnylam Pharmaceuticals Inc.（United States）
• Viking Therapeutics（United States）
• Galectin Therapeutics Inc.（United States）
• Akero Therapeutics, Inc.（United States）
• NGM Biopharmaceuticals, Inc.（United States）
• Poxel SA（France）

結論と推奨事項

Global Liver Cirrhosis Treatment Market size was valued at USD 17.76 billion in 2023 and is poised to grow from USD 18.9 billion in 2024 to USD 31.04 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

Cirrhosis of the liver, marked by significant liver damage and scarring, poses a major global health threat, especially given the rising prevalence of liver diseases linked to lifestyle changes. Key drivers for the growth of the liver cirrhosis treatment market include the escalating incidence of chronic liver diseases, which currently affect approximately 1.5 billion people worldwide, along with increasing alcohol consumption and poor dietary habits. Notably, non-alcoholic fatty liver disease (NAFLD) is emerging as the leading cause, with projections indicating its prevalence could reach 55.7% by 2040. Additionally, hepatitis B and C remain critical concerns, exacerbating the risk of cirrhosis and hepatocellular carcinoma, resulting in substantial mortality rates. Consequently, major pharmaceutical companies are intensifying their efforts to develop effective liver disease treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Cirrhosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Cirrhosis Treatment Market Segmental Analysis

Global Liver Cirrhosis Treatment Market is segmented by Disease Type, Treatment Type, End User and region. Based on Disease Type, the market is segmented into Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis and Cryptogenic Cirrhosis. Based on Treatment Type, the market is segmented into Immunosuppressants, Antibiotics, Vaccines, Anti-viral drugs and Corticosteroids. Based on End User, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Cirrhosis Treatment Market

The global liver cirrhosis treatment market is being significantly driven by the rising prevalence of liver diseases worldwide. Factors such as sedentary lifestyles, poor dietary choices, and the aging population have contributed to this increase. Additionally, the prevalence of autoimmune conditions like hepatitis and non-alcoholic fatty liver disease is also rising. Alcohol consumption further exacerbates liver health issues. The increased demand for effective hepatitis treatments has prompted healthcare organizations to invest in the development of innovative drugs, devices, and therapies, bolstered by support from biotechnology firms and research institutions. This competitive landscape is poised to create substantial growth opportunities for market participants, ensuring a prosperous future for the liver disease treatment sector.

Restraints in the Global Liver Cirrhosis Treatment Market

The Global Liver Cirrhosis Treatment market faces several restraints that hinder its growth trajectory. One of the primary challenges is the high cost associated with drugs, procedures, and surgeries needed to manage liver diseases, which significantly impacts market expansion. Additionally, inadequate healthcare services, particularly in rural or underserved regions, coupled with a lack of awareness regarding liver diseases and their symptoms among both the general public and healthcare professionals, further exacerbate the issue. Moreover, societal stigma surrounding certain liver conditions, such as those resulting from bacterial infections or alcohol, complicates treatment accessibility. Difficulties in liver transplantation, strict regulatory frameworks, and a scarcity of effective drugs under research and development also impede market progress, as substantial financial resources are necessary for treatment.

Market Trends of the Global Liver Cirrhosis Treatment Market

The Global Liver Cirrhosis Treatment market is poised for significant growth, driven by elevated research and development investments focusing on innovative therapies and targeted treatments for liver diseases. With a burgeoning awareness of liver health, enhanced healthcare services, and increased funding for prevention and diagnosis, the landscape is improving markedly. Furthermore, the aging population and rising disposable incomes in emerging markets are catalyzing demand for sophisticated healthcare solutions. Advances in surgical procedures and radiological interventions are also facilitating better treatment options, collectively propelling the market towards expansion and efficiency in managing liver cirrhosis and associated conditions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Liver Cirrhosis Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Alcoholic Cirrhosis
• Atrophic Cirrhosis
• Biliary Cirrhosis
• Cryptogenic Cirrhosis

Global Liver Cirrhosis Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Immunosuppressants
• Antibiotics
• Vaccines
• Anti-viral drugs
• Corticosteroids

Global Liver Cirrhosis Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Other

Global Liver Cirrhosis Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Treatment Type, End User)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viking Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galectin Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akero Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NGM Biopharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Poxel SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations